Dr Shapiro talks to ecancertv at TAT 2015 about the roles of cyclin dependent kinase (CDK) pathways as targets for anti-cancer therapy. He describes the potential of emerging CDK inhibitors in cancer treatment, and summarises the most promising developments in this research area.